Eliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has rocketed to the top of Bristol-Myers Squibb's sales charts. And company execs don't expect it to stop there.
Bristol-Myers Squibb and Pfizer's next-gen anticoagulant, Eliquis, may have rolled out at a snail's pace. But these days, the drug is topping Bristol-Myers' sales charts--and the company believes it will top the other drugs in its class before long.
AbbVie CEO and Chairman Rick Gonzalez gave a good update on Japan for hepatitis C treatment Viekira which entered a market in December already served by Harvoni from Gilead Sciences and Bristol-Myers Squibb product Daklinza.
Bristol-Myers Squibb, Pfizer and Eisai are targeting Japan's growing pharma market with a pair of deals in the cardiovascular and oncology spaces, signing back-loaded agreements to push new drugs in the country.
Bristol-Myers Squibb continues to take it on the chin in Japan in hepatitis C sales even as its global performance continues to handle the competition.
A clutch of big-name drugmakers have teamed up to digitize the drug formulation development process. AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline and Pfizer are involved with the initiative, which is aiming to develop digital tools and processes that spot nonviable molecules earlier in development.
Bristol-Myers Squibb has been riding high thanks to its lead in the ultrahot immuno-oncology space. But in Q4, it wasn't just its cancer stars that pitched in to help revenue beat expectations.
Osaka-based Ono Pharmaceutical is gearing up its sales force to boost sales of Opdivo (nivolumab) as sales look set to pick up quickly from ¥2.5 billion ($21 million) at the end of March 2015 to past ¥100 billion annually in the coming years, Nikkei Asian Review reports.
Thanks to an FDA decision over the weekend, Bristol-Myers Squibb's immunotherapy Opdivo has caught back up to Merck's Keytruda in melanoma. And it won a new combination approval from the FDA to boot.
Last month the U.K. drug cost watchdog nixed Bristol-Myers Squibb's immunotherapy Opdivo for use against lung cancer, saying in draft guidance that it just cost too much to justify approval. But NICE feels differently when it comes to using Opdivo against skin cancer, today recommending it for approval without even extracting a price cut.